ALEX study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients

(European Society for Medical Oncology) A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.